GARS1 and neuromuscular disease: Informative comparisons would include tissue from GarsNmf249/+ mice at additional time points during disease progression (particularly pre-onset), an equivalent analysis on Gars mutant mice that have milder phenotypes (i.e. GarsC201R/+ mice), as well as other phenotypically similar neuromuscular disease models, such as Nefl mutant mice, a model of CMT2E (Adebola et al., 2015; Zhu et al., 1997).